Nashi

1,000th alfapump® implant completed

Retrieved on: 
Thursday, July 6, 2023
Overload, EASL, Heart failure, Prevalence, Heart, Liver disease, Cancer, Quality of life, DSR, Patient, Brussels Stock Exchange, Ascites, Nashi, Cirrhosis, Medical imaging

The Company also reports that it has received all administrative clearances to start the US MOJAVE study of DSR 2.0 in congestive heart failure patients and expects to enroll the first patient imminently.

Key Points: 
  • The Company also reports that it has received all administrative clearances to start the US MOJAVE study of DSR 2.0 in congestive heart failure patients and expects to enroll the first patient imminently.
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “We developed the alfapump to transform the lives of patients with recurrent and refractory ascites due to liver disease.
  • A 63-year old alfapump patient from Canada said: “The alfapump changed my life.
  • I got lucky with the alfapump, my daily routine is getting back, with no pain and suffering, just feeling good